Prenumeration
Eevia Health Plc (”Eevia” or “the Company”) announced on Tuesday, March 19th, that the Company has received a grant of approx. SEK 2.7m (EUR 243k) from Business Finland for finalizing a development project for the documentation of bioactivity on Eevia’s products. Eevia executed the project in 2023 and submitted the final report in Q1-24, which has now been approved.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity analysis houses with a focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of comments on Eevia Health. Readers may assume that Analyst Group has received compensation for making the commentary. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.